The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Unapproved Drugs: The $7.5 Billion 505(b)(2) Opportunity Most Pharma Execs Are Ignoring DrugPatentWatch Transform Data into Market Domination Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Access to Unapproved Drugs: FDA Policies on Compassionate Use and Emergency Use Authorization EveryCRSReport.com